Clinical outcomes of solid organ transplant recipients with ehrlichiosis.

Abstract

Because of our experience with severe Ehrlichia infections in lung transplant recipients, we reviewed all cases of ehrlichiosis in solid organ transplant recipients at Barnes-Jewish Hospital in St. Louis, Missouri. Between 1996 and 2007, 25 cases of ehrlichiosis were identified. We retrospectively collected demographic, clinical, laboratory, and outcomes data, and we compared the 5 cases in lung transplant recipients with 20 cases in other solid organ transplant recipients (heart, 2; kidney, 13; liver, 5). The presenting symptoms in the majority of both groups consisted of fever and headache. Clinical outcomes were worse in the lung transplant group and included a greater need for intensive care unit treatment (80% vs. 20%, P=0.02), longer length of hospital stay (21 vs. 5 days, P=0.02), and propensity to develop acute lung injury or acute respiratory distress syndrome (60% vs. 10%, P=0.04). No mortalities occurred in either group of patients. In an endemic area, ehrlichiosis is not unusual in solid organ transplant recipients, and lung transplant recipients tend to have a more severe illness.

• Authors: K L Lawrence, M R Morrell, G A Storch, R R Hachem, E P Trulock
• Journal: Transplant infectious disease : an official journal of the Transplantation Society (Transpl Infect Dis) Vol. 11 Issue 3 Pg. 203-10 (Jun 2009) ISSN: 1399-3062 [Electronic] Denmark
• PMID: 19228344 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents

Topics

• Adult
• Aged
• Anti-Bacterial Agents (therapeutic use)
• Ehrlichia (classification, drug effects, genetics, isolation & purification)
• Ehrlichiosis (diagnosis, drug therapy, microbiology, physiopathology)
• Female
• Humans
• Lung Transplantation (adverse effects)
• Male
• Middle Aged
• Organ Transplantation (adverse effects)
• Prognosis
• Severity of Illness Index